Dec 12, 2024 8:00am EST Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Nov 21, 2024 8:00am EST Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Nov 18, 2024 8:00am EST Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Nov 13, 2024 4:06pm EST Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 08, 2024 8:01am EST Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Oct 31, 2024 9:00am EDT Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Sep 04, 2024 8:00am EDT Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 08, 2024 4:19pm EDT Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 09, 2024 8:01am EDT Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
May 15, 2024 8:01am EDT Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
